Novo Nordisk and Eli Lilly Slash Prices for Popular Weight Loss Drugs

Wegovy and Zepbound now cost significantly less for uninsured patients as FDA ends drug shortage designations.

Novo Nordisk has reduced the monthly price of its weight loss drug Wegovy to $499 for uninsured patients or those with non-covering insurance, down from $1,350.
The price cut is part of a direct-to-consumer program through NovoCare Pharmacy, which offers home delivery and patient support services.
Eli Lilly recently implemented similar price reductions for its weight loss drug Zepbound, with starter doses priced at $349 and higher doses at $499 through its self-pay program.
Both companies are addressing affordability and competition in the GLP-1 drug market, which has seen soaring demand due to the drugs' effectiveness in weight loss.
The FDA has removed Wegovy and Zepbound from its drug shortage list, requiring compounding pharmacies to cease producing off-brand versions by late May.